Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The company has developed a proprietary antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response. In addition, ALDR has a yeast-based manufacturing technology, MabXpress, which allows them to target diseases that traditionally have not been addressable by antibodies.
The company’s lead drug candidate, eptinezumab, is a novel monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) and is currently undergoing pivotal trials for the prophylaxis treatment of both chronic and frequent episodic migraine. ALDR also has a preclinical pipeline, and the initial candidate, ALD1910, is being developed for patients who have an inadequate response to therapeutics directed at CGRP. ALDR also has an equity stake in Vitaeris, a company which was formed in 2016 to take over the development of ALDR's former anti IL-6 candidate known as clazakizumab.
Foresite Capital estimates that migraine prevention is a multi-billion-dollar drug class in the U.S., and eptinezumab should also offer ex-U.S. partnering opportunities for ALDR. In the U.S., there are approximately 7 million patients diagnosed with high frequency episodic migraines (5-14 migraine days per month) and another 3 million patients with chronic migraines (15 or more migraine days per month). Given the large market size, Foresite Capital believes there will be sufficient room for multiple anti-CGRP drugs, and that eptinezumab’s competitive profile should allow it to capture meaningful share. In particular, eptinezumab’s IV formulation should capture a different segment of patients than the sub-cutaneous formulations of the other CGRP competitors.